Compare · BGXX vs DFTX
BGXX vs DFTX
Side-by-side comparison of Bright Green Corporation (BGXX) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGXX and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX carries a market cap of $4.65B.
- DFTX has hit the wire 7 times in the past 4 weeks while BGXX has been quiet.
- DFTX has more recent analyst coverage (6 ratings vs 0 for BGXX).
- Company
- Bright Green Corporation
- Definium Therapeutics Inc.
- Price
- $0.14-30.63%
- $42.64-1.16%
- Market cap
- -
- $4.65B
- 1M return
- -
- -4.79%
- 1Y return
- -
- +340.04%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 6
Latest BGXX
- Lynn Stockwell and Bright Green Corporation File $3 Billion Lawsuit Against Rodey Law Firm and Attorneys' Liability Assurance Society (ALAS) for Legal Malpractice and Bad Faith
- PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation "BGXXQ" Q and A
- Bright Green Corporation Merges with PharmAGRI Capital Partners; Lynn Stockwell Appointed CEO and Chairwoman
- SEC Form 25-NSE filed by Bright Green Corporation
- Bright Green Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Bright Green Corporation Announces the next steps for the completion of its restructuring plan
- Bright Green Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Financial Statements and Exhibits
- Bright Green Corporation Announces the completion of its restructuring plan, withdraws from the Cannabis business and sets course on the production of all DEA Scheduled Controlled Substances
- Bright Green Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Financial Statements and Exhibits
- Bright Green Corporation Has Signed Agreement with Majority Shareholder as Plan Sponsor on Prepackaged Plan to Restructure the Company.
Latest DFTX
- Wells Fargo initiated coverage on Definium Therapeutics with a new price target
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)